entertainment -WSS

entertainment

author：comprehensive 2025-09-29 20:52:57 - browse：74

Chief executive officer of Sanofi Paul Hudson, wearing glasses, speaks into a mic — pharma coverage from STAT — Sanofi CEO Paul Hudson Carolyn Kaster/AP

LONDON — Sanofi CEO Paul Hudson on Wednesday defended his company’s recent moves to abandon future profit guidance and up its investment in its own research programs, arguing that the dramatically negative market response didn’t reflect the potential rewards that could stem from the plan.

“Would I have liked the stock market reaction to be more generous? Of course,” Hudson said at a Financial Times event in London. “But this is a long-term game, and if you’re trying to deliver long-term value, you try not to make too many short-term decisions.”

Sanofi unveiled its R&D plans late last month as it announced its third-quarter performance and said that it was spinning out its consumer health division. As the company said it was going to spend more money on research, it also withdrew earnings outlooks for 2025. Company executives have argued that this was the moment — when Sanofi has a strong pipeline and isn’t facing patent expirations for years — to increase its R&D resources, even at the expense of short-term profits.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： Readout Newsletter: Blackstone Life Sciences, Merck, Bluebird Bio

hotspot

WSS

Readout Newsletter: Merck, Vertex, and Viking updates

Congress extends some pandemic preparedness programs

Roche subsidiary Foundation Medicine opens new headquarters

Study says nonprofit hospitals fall short in charity care spending

Will an HIV vaccine ever be a reality?

6 solutions to address cancer drug shortages and others

explore

entertainment

Wikipedia

As demand for Covid shots wanes, Moderna seeks its next success

Study says nonprofit hospitals fall short in charity care spending

Jerome Adams on the need for new antivirals for Covid

The biotech scorecard for Q4: 16 stock

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Scientists boost immune system in aging mice by making it youthful

Heart attack and stroke risk calculators need revising

The stability of $0 premiums in Medicare Advantage

How one medical school became remarkably diverse

There's no autism epidemic. It's an autism diagnosis epidemic

hotspot

Stop Congress from blocking public access to science

Lawsuit highlights wrinkle for disputes over surprise medical bills

CDC picks Alphabet's Verily for wasterwater surveillance contract

Experts study whether long Covid risk adds up with each reinfection

Readout Newsletter: Cardior, Regeneron, Nuvation, Dyne and more

Why the world’s most expensive drug might be worth the price

focus

hotspot

explore

entertainment